Fortrea Holdings Inc.
FTREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeFortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. At a $1.68B market cap, Fortrea Holdings Inc. ranks as a small-cap company within healthcare. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services.
Market Cap
$1.68B
Beta
2.01
P/E (TTM)
—
P/E (Fwd)
16.51
EPS (TTM)
$-4.77
EPS (Fwd)
$1.08
ROE
-64.5%
ROA
-0.1%
Cash
$147.5M
Total Debt
$1.12B
Free CF
$285.6M
52W Change
278.7%
Annual Financials
Cash vs Debt
The company holds $147.5M in cash, though total debt stands at $1.12B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $285.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -64.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $3.06B to $2.72B.
Fortrea Holdings Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Fortrea Holdings Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing FTRE.